Connor Clark & Lunn Investment Management Ltd. decreased its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 5.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,199,691 shares of the company's stock after selling 63,662 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 1.35% of Amylyx Pharmaceuticals worth $4,247,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently modified their holdings of AMLX. Valeo Financial Advisors LLC purchased a new stake in shares of Amylyx Pharmaceuticals during the first quarter valued at $35,000. Alpine Global Management LLC bought a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter worth approximately $45,000. R Squared Ltd boosted its stake in Amylyx Pharmaceuticals by 99.9% in the 1st quarter. R Squared Ltd now owns 12,736 shares of the company's stock valued at $45,000 after buying an additional 6,366 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Amylyx Pharmaceuticals by 18.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,188 shares of the company's stock valued at $61,000 after purchasing an additional 2,653 shares during the last quarter. Finally, Premier Path Wealth Partners LLC bought a new stake in shares of Amylyx Pharmaceuticals during the first quarter worth $72,000. Institutional investors own 95.84% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts have issued reports on AMLX shares. The Goldman Sachs Group upgraded Amylyx Pharmaceuticals to a "buy" rating and set a $10.00 price target for the company in a report on Thursday, July 10th. HC Wainwright raised their target price on Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the company a "buy" rating in a report on Friday, May 9th. Mizuho raised their price objective on Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the company an "outperform" rating in a report on Wednesday, May 14th. TD Cowen initiated coverage on Amylyx Pharmaceuticals in a research note on Friday, May 30th. They issued a "buy" rating on the stock. Finally, Guggenheim initiated coverage on Amylyx Pharmaceuticals in a research note on Tuesday, June 24th. They issued a "buy" rating and a $17.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $11.75.
Read Our Latest Stock Analysis on AMLX
Amylyx Pharmaceuticals Stock Performance
Shares of AMLX traded down $0.06 during mid-day trading on Monday, reaching $7.95. The company had a trading volume of 636,544 shares, compared to its average volume of 1,095,165. The firm has a 50-day moving average price of $7.10 and a 200 day moving average price of $5.15. Amylyx Pharmaceuticals, Inc. has a 52 week low of $2.05 and a 52 week high of $8.72. The company has a market capitalization of $708.46 million, a price-to-earnings ratio of -3.17 and a beta of -0.46.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.02). As a group, research analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.
About Amylyx Pharmaceuticals
(
Free Report)
Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
Featured Articles
Before you consider Amylyx Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.
While Amylyx Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access